Categorynews

Aptorum Group to Be Newly Added to MSCI HK Micro Cap Index

May 22, 2019 Off By BusinessWire

HONG KONG–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM) (“the Company”) a pharmaceutical
company dedicated to developing and commercializing a broad range of
therapeutic and diagnostic technologies to tackle unmet medical needs,
announced today the Company’s addition to the Morgan Stanley Capital
International MSCI (“MSCI”) Hong Kong Micro Cap Index, effective
Tuesday, May 28, 2019, Hong Kong Time.

MSCI Hong Kong Micro Cap Index is an international equity benchmark
recognized by institutional investors. Inclusion of constituent
companies is based on excellence of performance and potential of
development. We believe that our inclusion in the MSCI Hong Kong Micro
Cap Index will help expand Aptorum’s investor base and enhance its
corporate image and market presence.

Founder and Chief Executive Officer of Aptorum Group and Mr. Ian Huen
commented “We are honoured to be added as a constituent stock of the
MSCI Hong Kong Micro Cap Index. The inclusion reaffirms market
recognition of Aptorum’s performance in the aspect of maximizing
investors’ return, and we believe, in the near future, will increase
Aptorum’s visibility in the investment market and elevate Aptorum’s
market position.”

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing a broad range of therapeutic
and diagnostic technologies to tackle unmet medical needs. Aptorum Group
is pursuing therapeutic and diagnostic projects in neurology, infectious
diseases, gastroenterology, oncology and other disease areas as well as
non-therapeutic areas such as surgical robotics and the operations of
its medical clinic in Hong Kong, Talem Medical, with the initial focus
on treatment of chronic diseases resulting from modern sedentary
lifestyles and aging population.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited
and its future expectations, plans and prospects that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. For this purpose, any
statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue,” or the negative of these terms or other
similar expressions. Aptorum Group has based these forward-looking
statements largely on its current expectations and projections about
future events and trends that it believes may affect its business,
financial condition and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions including,
without limitation, risks related to its announced management and
organizational changes, the continued service and availability of key
personnel, its ability to expand its product assortments by offering
additional products for additional consumer segments, the company’s
anticipated growth strategies, anticipated trends and challenges in its
business, and its expectations regarding, and the stability of, its
supply chain, and the risks more fully described in Aptorum Group’s Form
20-F and other filings that Aptorum Group may make with the SEC in the
future. Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a result
of new information, future events or otherwise.